Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Vaccines against Mpox: Combating the Threat
share announcement

Vaccines against Mpox: Combating the Threat

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: closed (15 December 2024) | Viewed by 3503

Special Issue Editor

Dr. Lorenzo Subissi

E-Mail
Guest Editor
World Health Organization, Geneva, Switzerland
Interests: emerging viral diseases; virology; epidemiology

Special Issue Information

Dear Colleagues,

Vaccinology dates back to the times when viruses were not known, and the first vaccine was developed to combat smallpox. Since then, our understanding of the host adaptive immune responses to infectious diseases has led to the development of a variety of vaccine platforms and vaccine technologies to prevent morbidity and mortality from a wide range of infectious diseases. Some of these technologies are well established while some others are still under development.

In this Special Issue, we shed light onto the latest advances in the field of vaccines against orthopoxviruses, with focus on mpox, which still causes outbreaks at the global level and has a significant impact, including in children, in endemic settings.

Dr. Lorenzo Subissi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine efficacy
  • monkeypox
  • mpox
  • smallpox
  • immunity
  • surveillance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 240 KiB  
Article
Factors Related to Mpox-Vaccine Uptake among Men Who Have Sex with Men in Taiwan: Roles of Information Sources and Emotional Problems
by Mei-Feng Huang, Yu-Ping Chang, Chien-Wen Lin and Cheng-Fang Yen
Vaccines 2024, 12(3), 332; https://doi.org/10.3390/vaccines12030332 - 20 Mar 2024
Cited by 4 | Viewed by 1959
Abstract
An mpox outbreak occurred suddenly and rapidly spread worldwide in 2022. Research has demonstrated a link between the sexual behavior of men who have sex with men (MSM) and the contraction of mpox. This study assessed the factors related to mpox-vaccine uptake among [...] Read more.
An mpox outbreak occurred suddenly and rapidly spread worldwide in 2022. Research has demonstrated a link between the sexual behavior of men who have sex with men (MSM) and the contraction of mpox. This study assessed the factors related to mpox-vaccine uptake among MSM in Taiwan, focusing on the roles of information sources and emotional problems. In total, 389 MSM participated in an online survey. Data on the participants’ vaccination statuses; anxiety symptoms, which were assessed using the State–Trait Anxiety Inventory; depressive symptoms, which were assessed using the Center for Epidemiologic Studies Depression Scale; and risk perceptions of contracting mpox were collected. Factors related to mpox-vaccine uptake were examined using a multivariable logistic regression model. The results revealed that MSM who were older (p < 0.001), perceived a higher risk of contracting mpox (p = 0.040), and received mpox information from health-care providers (p < 0.001) were more likely to receive mpox vaccination, whereas MSM who reported a greater severity of depression (p = 0.017) were less likely to receive mpox vaccination. However, age did not moderate the associations of perceiving a higher risk of contracting mpox, receiving mpox information from health-care providers, and depression with having an mpox vaccination. Health-care providers should consider these factors when developing intervention programs for enhancing mpox-vaccine uptake among MSM. Full article
(This article belongs to the Special Issue Vaccines against Mpox: Combating the Threat)

Other

Jump to: Research

13 pages, 2564 KiB  
Systematic Review
Prevalence of Mpox Vaccine Acceptance Among Students: A Systematic Review and Meta-Analysis
by Ambanna Yappalparvi, Shilpa Gaidhane, G. Padmapriya, Irwanjot Kaur, Madan Lal, Suhaib Iqbal, G. V. Siva Prasad, Atreyi Pramanik, Promila Sharma, Praveen Malik, Teena Vishwakarma, Ankit Punia, Megha Jagga, Rachana Mehta, Sanjit Sah, Muhammed Shabil, Prakasini Satapathy, Ganesh Bushi, Ali Davod Parsa and Russell Kabir
Vaccines 2025, 13(2), 183; https://doi.org/10.3390/vaccines13020183 - 13 Feb 2025
Viewed by 1016
Abstract
Background: Mpox, formerly known as monkeypox, is a re-emerging viral disease. Vaccine acceptance is crucial for preventing its spread. This systematic review and meta-analysis assessed the acceptance of the Mpox vaccine among student populations. Methods: We searched electronic databases, including PubMed, Web of [...] Read more.
Background: Mpox, formerly known as monkeypox, is a re-emerging viral disease. Vaccine acceptance is crucial for preventing its spread. This systematic review and meta-analysis assessed the acceptance of the Mpox vaccine among student populations. Methods: We searched electronic databases, including PubMed, Web of Science, and Embase, up to 14 September 2024. The studies included were observational, such as cross-sectional and cohort studies, and specifically assessed vaccine acceptance for Mpox vaccines among students. R version 4.4 was used to perform the meta-analysis, and sensitivity analyses were conducted to assess the robustness of the findings. The publication bias was evaluated using Doi plots. Results: Of the 143 studies initially identified, eight studies were included in the final analysis, comprising a total of 16,129 participants. The overall vaccine acceptance rate was 58.6%, with considerable variability across studies (I2 = 100%). The sensitivity analyses indicated that acceptance rates ranged between 45% and 70%. The Doi plot demonstrated the presence of moderate publication bias. Conclusion: This systematic review and meta-analysis shows moderate acceptance of the Mpox vaccine among students. Future studies should investigate the factors influencing vaccine acceptance and design targeted strategies to improve coverage, which will be essential for controlling Mpox and ensuring successful vaccination campaigns. Full article
(This article belongs to the Special Issue Vaccines against Mpox: Combating the Threat)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop